Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Sep 19.

Published in final edited form as: Am J Manag Care. 2023 Aug;29(8):408–413. doi: 10.37765/ajmc.2023.89406

Table 4.

Cohort patients without a statin prescription by atherosclerotic cardiovascular disease (ASCVD) risk indication for statin therapy.

		ASCVD risk indication
	Overall	Yes	No	p-value
	n=288	n=141	n=147
Demographics
Age, Mean, years (SD)	48.6 (± 14.5)	53.6 (± 14.2)	43.9 (± 13.0)	<0.001^a
Sex % (n)				0.048^b
Male	39.6% (114)	45.4% (64)	34.0% (50)
Female	60.4% (174)	54.6% (77)	66.0% (97)
Race % (n)				0.260^b
Black	32.3% (93)	35.5% (50)	29.3% (43)
Non-Black	67.7% (195)	64.5% (91)	70.8% (104)
Clinical Variables
BMI ≥ 30 kg/m²	56.3% (162)	53.9% (76)	58.5% (86)	0.431^b
Comorbidities % (n)
NAFLD (diagnosed)	22.9% (66)	24.1% (34)	21.8% (32)	0.636^b
Diabetes	29.9% (86)	50.4% (71)	10.2% (15)	<0.001^b
Hypertension	61.8% (178)	77.3% (109)	46.9% (69)	<0.001^b
Hyperlipidemia	30.9% (89)	41.8% (59)	20.4% (30)	<0.001^b

^a

Two sample Student t test.

^b

Chi square test. ASCVD=atherosclerotic cardiovascular disease, as calculated by 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk.

SD=standard deviation. =body mass index. NAFLD=nonalcoholic fatty liver disease.